S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Stock market today: Asian world shares mostly lower after Wall St has its worst week in 6 months
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Oil prices have risen. That's making gas more expensive for US drivers and helping Russia's war
Writers Guild and Hollywood studios reach tentative agreement to end strike. No deal yet for actors
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Canadian autoworkers ratify new labor agreement with Ford
This Stock Could Go Up 66% or More. (Ad)
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
NASDAQ:DRMA

Dermata Therapeutics (DRMA) Stock Forecast, Price & News

$1.08
+0.01 (+0.46%)
(As of 09/22/2023 08:51 PM ET)
Compare
Today's Range
$1.07
$1.15
50-Day Range
$1.01
$1.60
52-Week Range
$0.94
$13.12
Volume
8,400 shs
Average Volume
1.18 million shs
Market Capitalization
$3.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Dermata Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
268.7% Upside
$4.00 Price Target
Short Interest
Healthy
0.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars


DRMA stock logo

About Dermata Therapeutics (NASDAQ:DRMA) Stock

Dermata Therapeutics, Inc., a clinical-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

DRMA Price History

DRMA Stock News Headlines

His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Dermata Therapeutics GAAP EPS of -$2.27
Why Is Allarity Therapeutics (ALLR) Stock Down 23% Today?
See More Headlines
Receive DRMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dermata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DRMA Company Calendar

Last Earnings
8/10/2023
Today
9/25/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRMA
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+268.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-9,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.82 per share

Miscellaneous

Free Float
2,889,000
Market Cap
$3.46 million
Optionable
Not Optionable
Beta
0.45
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Gerald T. Proehl (Age 64)
    Founder, Pres, CEO & Chairman
    Comp: $352.92k
  • Mr. David F. Hale (Age 74)
    Co-Founder & Lead Independent Director
    Comp: $18.12k
  • Ms. Kyri K. Van Hoose CPA (Age 44)
    M.B.A., Sr. VP & CFO
    Comp: $328.75k
  • Dr. Christopher J. Nardo M.P.H. (Age 58)
    Ph.D., Sr. VP & Chief Devel. Officer
    Comp: $329.92k
  • Mr. Sean Proehl
    Sr. Director of Legal & Bus. Devel.
  • Dr. Maria Bedoya Toro Munera M.B.A. (Age 71)
    Ph.D., Sr. VP of Regulatory Affairs & Quality Assurance













DRMA Stock - Frequently Asked Questions

Should I buy or sell Dermata Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dermata Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DRMA shares.
View DRMA analyst ratings
or view top-rated stocks.

What is Dermata Therapeutics' stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month price targets for Dermata Therapeutics' shares. Their DRMA share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 268.7% from the stock's current price.
View analysts price targets for DRMA
or view top-rated stocks among Wall Street analysts.

How have DRMA shares performed in 2023?

Dermata Therapeutics' stock was trading at $6.5440 at the start of the year. Since then, DRMA shares have decreased by 83.4% and is now trading at $1.0850.
View the best growth stocks for 2023 here
.

Are investors shorting Dermata Therapeutics?

Dermata Therapeutics saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 600 shares, a decrease of 95.8% from the August 15th total of 14,400 shares. Based on an average daily trading volume, of 175,900 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.
View Dermata Therapeutics' Short Interest
.

When is Dermata Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our DRMA earnings forecast
.

How were Dermata Therapeutics' earnings last quarter?

Dermata Therapeutics, Inc. (NASDAQ:DRMA) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.63) earnings per share for the quarter.

When did Dermata Therapeutics' stock split?

Shares of Dermata Therapeutics reverse split on Tuesday, March 14th 2023. The 1-16 reverse split was announced on Tuesday, March 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

When did Dermata Therapeutics IPO?

(DRMA) raised $18 million in an initial public offering on Friday, August 13th 2021. The company issued 2,571,428 shares at a price of $7.00 per share.

What is Dermata Therapeutics' stock symbol?

Dermata Therapeutics trades on the NASDAQ under the ticker symbol "DRMA."

Who are Dermata Therapeutics' major shareholders?

Dermata Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (2.41%), Virtu Financial LLC (1.37%) and Citadel Advisors LLC (0.54%).

How do I buy shares of Dermata Therapeutics?

Shares of DRMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dermata Therapeutics' stock price today?

One share of DRMA stock can currently be purchased for approximately $1.09.

How much money does Dermata Therapeutics make?

Dermata Therapeutics (NASDAQ:DRMA) has a market capitalization of $3.46 million. The company earns $-9,610,000.00 in net income (profit) each year or ($8.02) on an earnings per share basis.

How can I contact Dermata Therapeutics?

The official website for the company is www.dermatarx.com. The company can be reached via phone at 858-800-2543 or via email at sproehl@dermatarx.com.

This page (NASDAQ:DRMA) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -